Figure 4.

lncRNA MYU knockdown inhibits the proliferation of TE-2 cells. (A) The relative expression level of lncRNA MYU in esophageal squamous cell carcinoma cells transfected with control siRNA or lncRNA MYU siRNA was analysed by reverse transcription-quantitative PCR. ^*P<0.05 vs. control. (B) Cell cycle analysis was performed after TE-2 cells were transfected with control siRNA or lncRNA MYU siRNA-2. (C) Representative cell cycle profiles obtained by flow cytometry and quantified proportions of cells in the different phases of the cell cycle. ^*P<0.05 vs. control. (D) Bar graph presenting the expression of lncRNA MYU, E-cadherin, Vimentin and Ki-67 relative to that of GAPDH in TE-2 cells transfected with control siRNA or lncRNA MYU siRNA-2. ^*P<0.05 vs. control. (E) A wound-healing assay was used to evaluate the migration ability of TE-2 cells transfected with control siRNA or lncRNA MYU siRNA-2. (F) The invasiveness of TE-2 cells transfected with control siRNA or lncRNA MYU siRNA-2 was evaluated using a Transwell assay. (G) Bar graph presenting the number of invasive TE-2 cells transfected with control siRNA or lncRNA MYU siRNA. ^*P<0.05 vs. control. (H) A Cell Counting Kit-8 assay was performed in TE-2 cells transfected with control siRNA or lncRNA MYU siRNA-2. ^*P<0.05 vs. control. lncRNA, long non-coding RNA; MYU, c-Myc upregulated lncRNA; siRNA, small interfering RNA; OD, optical density.